Timothy Barberich

HeartWare Pty. Ltd. develops and manufactures implantable circulatory assist devices. Its devices are used in treating patients with congestive heart failure. The company is headquartered in Sydney, Australia.

Resolvyx Pharmaceuticals, Inc. discovers and develops therapeutics for inflammatory diseases. Its products include RX-10001, RX-10045 and RX-20001. The firm's focus is to develop a new class of medicines called Resolvins for the treatment of a range of ophthalmic diseases. The company was founded by Daniel Goodman, Charles N. Serhan, Per Gjorstrup and Thomas E. Van Dyke in June 20, 2001 and is headquartered in Cambridge, MA.

Neurovance, Inc. operates as a a biopharmaceutical company. It develops treatments for central nervous system disorders. The company was founded by Anthony McKinney and Franklin P. Bymaster in 2011 and is headquartered in Cambridge, MA.

Gemin X Pharmaceuticals US Inc. is engaged in the development of cancer therapeutics. It offers mimetic and telomere capping programs, as well as screening, medicinal chemistry, and preclinical development services. The company was founded by Gordon C. Shore in 1998 and is headquartered in Malvern, PA.

Boston Medical Center provides healthcare services. It provides a spectrum of pediatric and adult care services from primary to family medicine specialty care. The hospital is established in July 1996 and is headquartered in Boston, MA

Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC.

Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA.

HeartWare, Inc. manufactures electro medical and electrotherapeutic apparatus. The company develops implantable circulatory assist devices, which are used in treating patients with congestive heart failure problems. The company was established in 2003 and is headquartered in Miramar, FL

Bionevia Pharmaceuticals, Inc. operates as a chronic disease hospital. Timothy Joseph Barberich has been the CEO of the American company since 2008.

HeartWare International LLC is a medical device company, which engaged in the development and manufacturing of miniaturized implantable heart pumps or ventricular assist devices to treat patients suffering from advanced heart failure. The company was founded on July 29, 2008 and is headquartered in Framingham, MA.

Euthymics Bioscience, Inc. develops a novel medicine for alcohol use disorder (AUD) and smoking cessation. It engages in developing a medicine for central nervous system disorders of significant unmet medical need, including major depressive disorder (MDD) and alcohol use disorder (AUD). The firm provides Amitifadine, an antidepressant for major depressive disorder. The firm focuses on the modulation of neurotransmitters, including serotonin (5-HT), norepinephrine (NE), and dopamine (DA). The company was founded by Anthony A. McKinney and Franklin P. Bymaster in 2009 and is headquartered in Cambridge, MA.

Part of Cephalon, Inc., Gemin X Pharmaceuticals Canada, Inc. is a private company based in Montréal, Canada.

MirImmune, Inc. is a biopharmaceutical company that develops new generation immunotherapies for cancer. It combines two approaches to cancer treatment: immune checkpoint inhibition and cell-based immunotherapies. The company was founded by Alexey V. Eliseev, Alexey Wolfson, and Timothy Joseph Barberich on May 18, 2015 and is headquartered in Boston, MA.

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the business of developing therapeutics to activate a person's innate regenerative potential to restore function. The firm is also involved in creating and commercializing therapeutics to potentially transform the lives of individuals by repairing or reversing damage done to cells, tissue, and organs. The company was founded by Robert S. Langer, David L. Lucchino, Christopher R. Loosey, and Will J. McLean on November 13, 2014 and is headquartered in Lexington, MA.